July 10, 2020Journal of Cardiovascular Medicine
Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality
Key result
Anti-inflammatory therapies for pericarditis, including NSAIDs, corticosteroids, colchicine, and anakinra, do not appear contraindicated during COVID-19 infection and should not be discontinued.
Why the study?
During the COVID-19 pandemic, clinicians faced uncertainty regarding the safety of anti-inflammatory therapies for pericardial diseases in patients with or at risk for SARS-CoV-2 infection.
Are anti-inflammatory therapies for pericarditis safe to continue or initiate in patients with concurrent COVID-19 infection?
Population
Patients with pericarditis who become infected with SARS-CoV-2, and patients with COVID-19 who develop…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports continuing pericarditis anti-inflammatory therapy in COVID-19; leaves open need for prospective validation.
Structured PICO
Are anti-inflammatory therapies for pericarditis safe to continue or initiate in patients with concurrent COVID-19 infection?
P
Population
Patients with pericarditis who become infected with SARS-CoV-2, and patients with COVID-19 who develop pericarditis or pericardial effusion
I
Intervention
Anti-inflammatory therapies (NSAIDs, corticosteroids, colchicine, and biological agents such as anakinra)
O
Outcome
Safety and continuation of pericarditis therapies during COVID-19 infectionsafety
Standard anti-inflammatory therapies for pericarditis, including NSAIDs, colchicine, and corticosteroids, appear safe to continue in patients who develop COVID-19.
Cite This Study
Imazio et al. (2020) conducted a review in Pericardial diseases and COVID-19. Anti-inflammatory therapies (NSAIDs, corticosteroids, colchicine, anakinra) was evaluated. Anti-inflammatory therapies for pericarditis, including NSAIDs, corticosteroids, colchicine, and anakinra, do not appear contraindicated during COVID-19 infection and should not be discontinued.